

Extract of *Artemisia lavandulaefolia* Inhibits In Vitro Angiogenesis in Human Umbilical Vein Endothelial Cells

SHORT
COMMUNICATIONEui-Yeun Yi¹, Kyung-Suk Han², Yung-Jin Kim¹¹Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Korea, ²Biochem c.a.l.s., Ltd., Institute of Molecular Biology and Genetics, Seoul National University, Seoul, Korea

Angiogenesis is important processes for tumor growth and metastasis. Anti-angiogenesis target therapy has recently been known to be new anti-cancer therapeutic strategies. Natural products such as traditional medicine comprise a major source of angiogenesis inhibitors. *Artemisia lavandulaefolia* has been known to use in the traditional medical practices. However, its molecular mechanism on the tumor protection and therapy was not clearly elucidated. In this study, we investigated the possibility that extract of *A. lavandulaefolia* inhibits in vitro angiogenesis. Therefore, we examined the effect of extract of *A. lavandulaefolia* on the vascular network formation of human umbilical vein endothelial cells (HUVECs). We found that the treatment of *A. lavandulaefolia* extract suppressed the tube formation of HUVECs without any influence on the viability of HUVECs. In addition, extract of *A. lavandulaefolia* inhibited the migration and invasion of HUVECs. These results suggest that extract of *A. lavandulaefolia* could be act for an angiogenic inhibitor.

(J Cancer Prev 2014;19:247-252)**Key Words:** Angiogenesis, Natural products, *Artemisia lavandulaefolia*, Tumor

INTRODUCTION

Angiogenesis is a process of remodeling such as sprouting and growth of blood vessels.¹ It is regulated under the control of balance between stimulators and inhibitors.² In addition, angiogenesis involve complex and diverse cellular actions such as degradation of extracellular matrix, proliferation and migration of endothelial cells, and morphological differentiation of endothelial cells to form tubes.^{3,4}

Many traditional oriental medicines consist of medicinal products from plants and animals that are used for treatments.⁵ It has been practiced in China, Korea, Japan, and other Asian countries for many centuries.⁶ In many cases, traditional medicinal products showed anti-tumor activities and they have been considered as candidates for novel cancer therapeutics.^{7,8}

Artemisia lavandulaefolia is the Chrysanthemum family plant and is used in traditional medicine as a perennial plant that is

widely distributed in Korea.⁹ As well as being used as food material, *A. lavandulaefolia* has been used for the treatment of various diseases in traditional medicine in Korea.¹⁰ *A. lavandulaefolia* has been used as a digestive, anthelmintic, and effective odor remover. In addition, *A. lavandulaefolia* has known effects about gastrointestinal diseases, constipation, pain, belly pain, asthma, and gynecological problems.¹⁰ Recently, it has been reported that *A. lavandulaefolia* has anti-bacterial and anti-fungal activity against many kinds of the pathogenic bacterium and fungi in the Chinese medicine.¹¹⁻¹⁴

Although many studies on the effects of *A. lavandulaefolia* have been conducted, no exists the information concerning relationship with angiogenesis and its molecular mechanisms. Therefore, we examined the anti-angiogenic effects by *A. lavandulaefolia* in human umbilical vein endothelial cells (HUVECs).

Received December 2, 2014, Revised December 12, 2014, Accepted December 12, 2014

Correspondence to: Yung-Jin KimDepartment of Molecular Biology, College of Natural Science, Pusan National University, 2 Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan 609-735, Korea
Tel: +82-51-510-2176, Fax: +82-51-513-9258, E-mail: yjinkim@pusan.ac.kr

Copyright © 2014 Korean Society of Cancer Prevention

©This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

MATERIALS AND METHODS

1. Materials and reagents

HUVECs were purchased from InnoPharmaScreen Inc. (Asan, Korea). Basic fibroblast growth factor (bFGF) and heparin were obtained from PeproTech Inc. (Rocky Hill, NJ, USA). M199, fetal bovine serum (FBS), penicillin and streptomycin were purchased from WELGEN Inc. (Daegu, Korea). Matrigel was purchased from Collaborative Biomedical Products (Bedford, MA, USA) and used for the tube formation assay. Trans-well filter chambers (8- μ m pores) were purchased from Corning-Costar (Cambridge, MA, USA).

2. Preparation of *Artemisia lavandulaefolia* extract

A. lavandulaefolia was purchased from Kyeongdong Medicinal Herb Market (Seoul, Korea). The biomass was dried root and leaf of *A. lavandulaefolia*. It was converted to a powdered form by cold-extraction using grain alcohol, and was sonicated at room temperature and ambient pressure. The *A. lavandulaefolia* extract was mixed with 70% grain alcoholic solution (30% pure water). The concentration of *A. lavandulaefolia* was 100 mg/mL, and the extract was diluted in distilled water. Finally, we used 50, 100, 500, and 1,000 μ g/mL *A. lavandulaefolia* for cytotoxic tests and used 100 μ g/mL for in vitro angiogenesis assays.

3. Cell culture

HUVECs were grown in M199, supplemented with heat-inactivated 20% FBS (WELGEN Inc.), 20 ng/mL of bFGF, 100 units/mL of penicillin and 100 μ g/mL of streptomycin in a 37°C incubator with a humidified atmosphere containing 5% CO₂.

4. MTT assay for cell viability

The effect of extract of *A. lavandulaefolia* on the viability of HUVECs was determined using the MTT assay, which is based on the conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) to insoluble MTT-formazan by cleavage of the tetrazolium ring by mitochondrial dehydrogenase enzymes in living cells. Briefly, HUVECs were grown in M199 with 20% FBS at a density of 2×10^4 cells on 24-well culture plates. After one night, the media was re-placed with M199 containing 1% FBS, and crude extract of *A. lavandulaefolia* and the cells were then incubated for 24 hours at 37°C under a humidified atmosphere that was comprised of 5% CO₂. Cells were treated with various concentrations of extract of *A. lavandulaefolia* (50, 100, 500 mg, and 1 mg). Next, MTT solution (5 mg/mL in H₂O) was added to the well, followed by the addition of 0.3 mL of dimethyl sulfoxide to

dissolve the MTT-formazan. The amount of MTT-formazan was then determined by measuring the absorbance at 540 nm. Each sample was assayed in triplicate, and the experiment was repeated three times.

5. In vitro tube formation assay

Before performing the test, 0.3 mL matrigel was transferred to 24-well plate and incubated for 30 minutes. HUVECs (2×10^4 cells) were plated on a layer of polymerized matrigel and treated with or without extract of *A. lavandulaefolia* at 37°C for 24 hours. Cell morphological changes were captured through a phase contrast microscope and photographed at 40 \times magnification. Each sample was assayed in duplicate, and independent experiments were repeated three times.

6. In vitro wounding migration assay

HUVECs were seeded onto 24-well culture plate until confluence and left overnight. Media was aspirated the next day, and cells were scratched with a 200 μ L pipette tip along the diameter of the well. Cells were washed twice with PBS and incubated at 37°C and 5% CO₂. After wounding, the cells were incubated in M199 with 1% serum, 1 mM thymidine, and/or extract of *A. lavandulaefolia*. These culture conditions minimized proliferation of HUVECs. Wound diameters were photographed at 24 hours. Wound closure was determined with optical microscopy at 40 \times magnification. Each sample was assayed in duplicate, and independent experiments were repeated three times.

7. In vitro invasion assay

Invasion assay was performed using a trans-well chambers system (Corning Inc., Cambridge, MA, USA) with 8.0- μ m pore polycarbonate filter inserts. The upper side of trans-well was coated with 10 μ L of matrigel (0.5 mg/mL) at room temperature for 1 hour. Complete media was plated in the lower parts of the trans-well chamber filters, and HUVECs (2×10^4 cells) and extract of *A. lavandulaefolia* in serum-free media were placed in the upper part. Cells were incubated at 37°C for 24 hours, fixed with methanol, and then stained with hematoxyline/eosin. Cells on the upper surface of the filter membrane were removed by wiping with a cotton swab. Invaded cells were determined with optical microscopy at 40 \times magnification. Each sample was assayed in duplicate, and independent experiments were repeated three times.

3. Extract of *Artemisia lavandulaefolia* inhibit migration and invasion of human umbilical vein endothelial cells

Endothelial cell migration and invasion are one of the critical steps in the formation of new blood vessels.¹⁵ Therefore, we investigated the effect of extract of *A. lavandulaefolia* on the movement of HUVECs from a wounded edge to an open area by wound healing assay. Treatment with *A. lavandulaefolia* extract

for 24 hours markedly decreased the migration of HUVECs compared with that of control (Fig. 3A). Migration of endothelial cells was decreased by about 63% by *A. lavandulaefolia* extract treatment compared with that of control (Fig. 3B).

To examine the effect of extract of *A. lavandulaefolia* on the invasiveness of HUVECs, we performed invasion assay with a trans-well system. Trans-wells were prepared such that the upper sides of the filter were coated with matrigel, and used for invasion assay. Extract of *A. lavandulaefolia* inhibited the




Figure 3. Extract of *Artemisia lavandulaefolia* inhibits migration of human umbilical vein endothelial cells. (A) Migration ability of HUVECs was measured by wound healing assay ($\times 40$). (B) Migrated cells were quantified under a phase-contrast microscope and photographed. This independent experiment was repeated three times.




Figure 4. Extract of *Artemisia lavandulaefolia* inhibits invasion of human umbilical vein endothelial cells. (A) Invasion capacity was examined using a trans-wells system coated with matrigel ($\times 40$). (B) Invaded cells were quantified under a phase-contrast microscope and photographed. This independent experiment was repeated three times.

invasiveness of HUVECs compared with that of control after 24 hours of incubation (Fig. 4A). The invasiveness of endothelial cells was inhibited by about 62% by *A. lavandulaefolia* extract treatment compared with that of control (Fig. 4B). Taken together, extract of *A. lavandulaefolia* strongly suppressed the migration and invasion of HUVECs.

DISCUSSION

Angiogenesis is the developmental process of new capillaries by sprouting from pre-existing vasculature,^{16,17} and is required as a significant component of a wide variety of physiological process and pathological conditions.¹⁸ In 1971, Folkman¹⁵ was firstly built up that angiogenesis is essential process in tumor growth. Since then, angiogenesis have been recognized as important strategies for cancer therapy.^{19,20} Angiogenesis are initiated by the secreted growth factors, chemokines/cytokines and other mediators.³ Tumor initiation and progression are also closely linked to angiogenesis. Thus, angiogenic responses in tumor could be targets for development of anti-cancer therapeutic drugs.⁵

The studies for novel anti-cancer drugs from natural products have been continued through the research of scientists worldwide in looking for new bio-active compounds.²⁰ *A. lavandulaefolia* is one of the traditional medicinal products and is usually used for food materials.¹¹ Effects of *A. lavandulaefolia* have been known to use for treatment in the traditional medicinal field. However, scientific studies on the effects of *A. lavandulaefolia* were not clearly elucidated. Recently, *A. lavandulaefolia* has been known to show anti-bacterial and anti-fungal effects. *A. lavandulaefolia* has been also reported that it has induced apoptosis and necrosis of hela cells.²¹

In this study, we investigated whether extract of *A. lavandulaefolia* has anti-angiogenic activities in HUVECs. The MTT assay was first carried out. Because the MTT assay is one of the most widely used in cell viability assay, which measures the cytotoxicity of molecules. The result is that extract of *A. lavandulaefolia* did not affect the viability of HUVECs (Fig. 1). This result was expected because extract of *A. lavandulaefolia* widely using as food materials. To determine the effect on the anti-angiogenesis of extract of *A. lavandulaefolia*, we examined in vitro tube formation assay. It is important step of angiogenesis which promote morphological differentiation into capillary-like structure. In the absence of extract of *A. lavandulaefolia*, HUVECs formed capillary-like networks. However, tube-like structure was suppressed in the presence of extract of *A. lavandulaefolia* in HUVECs (Fig. 2). Endothelial cell migration and invasion are

fundamental step during angiogenesis.⁴ Therefore, we determined the effect of extract of *A. lavandulaefolia* on the migration and invasion of HUVECs. As shown in Figures 3 and 4, migration and invasion were remarkably reduced by treatment extract of *A. lavandulaefolia* in HUVECs.

Research of the functional ingredients from the traditional medicinal products is very important for therapy development. Chemical composition of *A. lavandulaefolia* essential oil has been previously reported in several studies.^{22,23} The main components of *A. lavandulaefolia* essential oil was reported caryophyllene, b-thujone, eucalytol and b-farnesene.²⁴ However, the numerous activities of these components for medical therapy were not clearly elucidated. Thus, a functional study of the chemical composition of traditional medicine material will be added for effective disease treatment.

In summary, the major findings reported here are that extract of *A. lavandulaefolia* inhibited angiogenesis in HUVECs. Therefore, extract of *A. lavandulaefolia* may have potential to be a useful angiogenesis inhibitor. Further study is required to elucidate the mechanism of action on angiogenesis by extract of *A. lavandulaefolia*.

ACKNOWLEDGEMENTS

This work was supported by a 2-Years Research Grant of Pusan National University.

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

REFERENCES

1. Folkman J, Shing Y. Angiogenesis. *J Biol Chem* 1992;267:10931-4.
2. Siddiqui FA, Desai H, Siddiqui TF, Francis JL. Hemoglobin induces the expression and secretion of vascular endothelial growth factor from human malignant cells. *Hematol J* 2002;3:264-70.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature* 2000;407:249-57.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. *Nature* 2005;438:967-74.
5. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. *Trends Mol Med* 2007;13:353-61.
6. Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, et al. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. *Br J Cancer* 2012;107:411-6.

7. Morishita S, Shoji M, Oguni Y, Ito C, Higuchi M, Sakanashi M. Pharmacological actions of "kyushin," a drug containing toad venom: cardiotoxic and arrhythmogenic effects, and excitatory effect on respiration. *Am J Chin Med* 1992;20:245-56.
8. Qi F, Li A, Zhao L, Xu H, Inagaki Y, Wang D, et al. Cinobufacini, an aqueous extract from *Bufo bufo gargarizans* Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. *J Ethnopharmacol* 2010;128:654-61.
9. Han DR, Kim IH. Studies on the volatile oil constituents in *Artemisia* sp.: isolation and determination of camphor by gas chromatography. *Korea J Pharmacog* 1973;4:71-4.
10. Huh J. Herbal donguibogam. *Minjung-sa*, p 184, 1978.
11. Lee HO, Han KY, Han DM. Antibacterial and antifungal effect by *Artemisia lavandulaefolia* essential oil. *Korean J Food Nutr* 1999;12:559-63.
12. Wink M. Plant breeding, importance of plant secondary metabolites for protection against pathogens and herbivores. *Theor Appl Gen* 1988;75:225-33.
13. Wink M, Twardowski T. Allelochemicals properties as alkaloids. Effects on plants, bacteria and protein biosynthesis. In: eds, by Rizvi SJH and Rizvi V. *Allelopathy*. London; New York. Chapman & Hall, pp 129-50, 1992.
14. Won Yun K, Kil BS, Han DM. Phytotoxic and antimicrobial activity of volatile constituents of *Artemisia princeps* var. *orientalis*. *J Chem Ecol* 1993;19:2757-66.
15. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1971;285:1182-6.
16. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. *Cancer Sci* 2006;97:439-47.
17. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005;5:749-59.
18. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. *Curr Opin Genet Dev* 2010;20:65-71.
19. Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. *Curr Drug Targets Inflamm Allergy* 2005;4:3-8.
20. da Rocha AB, Lopes RM, Schwartzmann G. Natural products in anticancer therapy. *Curr Opin Pharmacol* 2001;1:364-9.
21. Zhang LM, Lv XW, Shao LX, Ma YF, Cheng WZ, Gao HT. Essential oil from *Artemisia lavandulaefolia* induces apoptosis and necrosis of hela cells. *Zhong Yao Cai* 2013;36:1988-92.
22. Pan JG1, Xu ZL, Ji L. Chemical studies on essential oils from 6 *Artemisia* species. *Zhongguo Zhong Yao Za Zhi* 1992;17:741-4, 764.
23. Cha JD, Jeong MR, Choi HJ, Jeong SI, Moon SE, Yun SI, et al. Chemical composition and antimicrobial activity of the essential oil of *Artemisia lavandulaefolia*. *Planta Med* 2005;71:575-7.
24. Liu ZL, Liu QR, Chu SS, Jiang GH. Insecticidal activity and chemical composition of the essential oils of *Artemisia lavandulaefolia* and *Artemisia sieversiana* from China. *Chem Biodivers* 2010;7:2040-5.